Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Endosomal TLRs play an important role in innate immune response as well as in autoimmune processes. In the therapy of systemic lupus erythematosus, antimalarial drugs chloroquine, hydroxychloroquine, and quinacrine have been used for a long time. Their suppression of endosomal TLR activation has been attributed to the inhibition of endosomal acidification, which is a prerequisite for the activation of these receptors. We discovered that chloroquine inhibits only activation of endosomal TLRs by nucleic acids, whereas it augments activation of TLR8 by a small synthetic compound, R848. We detected direct binding of antimalarials to nucleic acids by spectroscopic experiments and determined their cellular colocalization. Further analysis revealed that other nucleic acid-binding compounds, such as propidium iodide, also inhibited activation of endosomal TLRs and colocalized with nucleic acids to endosomes. We found that imidazoquinolines, which are TLR7/8 agonists, inhibit TLR9 and TLR3 even in the absence of TLR7 or TLR8, and their mechanism of inhibition is similar to the antimalarials. In contrast to bafilomycin, none of the tested antimalarials and imidazoquinolines inhibited endosomal proteolysis or increased the endosomal pH, confirming that inhibition of pH acidification is not the underlying cause of inhibition. We conclude that the direct binding of inhibitors to nucleic acids mask their TLR-binding epitope and may explain the efficiency of those compounds in the treatment…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In phagocytic cells, the deacidification of endosomes using pharmacological inhibitors like chloroquine has been shown to reduce endosomal toll-like receptor (TLR) response (de Bouteiller et al., 2005; Fox, 2019; Kuznik et al., 2011; Wozniacka et al., 2006; Yang et al., 2016)”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Kuznik et al., 2011
In the citing paper
“Hydroxychloroquine (HCQ) is an approved anti-malaria drug, and accumulation of hydroxychloroquine inhibits the binding ability of TLR9 to DNA and subsequent immune activation (77).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [77]
Citations
Cites
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
ACIDIFICATION OF THE ENDOCYTIC AND EXOCYTIC PATHWAYS
Mellman, I., Fuchs, R., & Helenius, A. (1986) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.55.070186.003311 · Cited by 2,032
Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
Leadbetter, E. A., Rifkin, I. R., Hohlbaum, A. M., Beaudette, B. C., Shlomchik, M. J., & Marshak-Rothstein, A. (2002) · Nature · doi:10.1038/416603a · Cited by 1,900
Yoshimori, T., Yamamoto, A., Moriyama, Y., Futai, M., & Tashiro, Y. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)47429-2 · Cited by 1,328
Toll-like receptors in systemic autoimmune disease
Marshak-Rothstein, A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1957 · Cited by 1,116
Barrat, F. J., Meeker, T., Gregorio, J., Chan, J. H., Uematsu, S., Akira, S., Chang, B., Duramad, O., & Coffman, R. L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050914 · Cited by 928
Human lupus autoantibody–DNA complexes activate DCs through cooperation of CD32 and TLR9
Means, T. K., Latz, E., Hayashi, F., Murali, M. R., Golenbock, D. T., & Luster, A. D. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523025 · Cited by 849
Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8
Gorden, K. B., Gorski, K. S., Gibson, S. J., Kedl, R. M., Kieper, W. C., Qiu, X., Tomai, M. A., Alkan, S. S., & Vasilakos, J. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1259 · Cited by 683
Häcker, H., Mischak, H., Miethke, T., Liptay, S., Schmid, R., Sparwasser, T., Heeg, K., Lipford, G. B., & Wagner, H. (1998) · The EMBO Journal · doi:10.1093/emboj/17.21.6230 · Cited by 653
The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor
Ewald, S. E., Lee, B. L., Lau, L., Wickliffe, K. E., Shi, G.-P., Chapman, H. A., & Barton, G. M. (2008) · Nature · doi:10.1038/nature07405 · Cited by 617
Research works printed but not linked: 2
- Ahmad-Nejad, 2002, Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments, Eur. J. Immunol., 32, 1958, 10.1002/1521-4141(200207)32:7<1958::aid-immu1958>3.0.co;2-u · DOI · Paper page
- Peacocke, 1973, Acridines, 723
Cited by
Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Mechanisms of action of hydroxychloroquine and chloroquine:implications for rheumatology
Schrezenmeier, E., & Dörner, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0372-x · Cited by 1,468
Systemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
Lysosomes as a therapeutic target
Bonam, S. R., Wang, F., & Muller, S. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0036-1 · Cited by 759
Emerging Role of Endosomal Toll-Like Receptors in Rheumatoid Arthritis
Thwaites, R., Chamberlain, G., & Sacre, S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00001 · Cited by 748
The Pathogenesis of the Antiphospholipid Syndrome
Giannakopoulos, B., & Krilis, S. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1112830 · Cited by 688
Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., & Sève, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102567 · Cited by 658
Zhou, D., Dai, S.-M., & Tong, Q. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa114 · Cited by 600
Toll-like receptors activation, signaling, and targeting: an overview
El-Zayat, S. R., Sibaii, H., & Mannaa, F. A. (2019) · Bulletin of the National Research Centre · doi:10.1186/s42269-019-0227-2 · Cited by 556
Mahévas, M., Tran, V.-T., Roumier, M., Chabrol, A., Paule, R., Guillaud, C., Fois, E., Lepeule, R., Szwebel, T.-A., Lescure, F.-X., et al. (2020) · BMJ · doi:10.1136/bmj.m1844 · Cited by 566
Network-based approach to prediction and population-based validation of in silico drug repurposing
Cheng, F., Desai, R. J., Handy, D. E., Wang, R., Schneeweiss, S., Barabási, A.-L., & Loscalzo, J. (2018) · Nature Communications · doi:10.1038/s41467-018-05116-5 · Cited by 552
Dissecting negative regulation of Toll-like receptor signaling
Kondo, T., Kawai, T., & Akira, S. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.05.002 · Cited by 419
Therapeutic options for targeting inflammatory osteoarthritis pain
Conaghan, P. G., Cook, A. D., Hamilton, J. A., & Tak, P. P. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0221-y · Cited by 405
Yalavarthi, S., Gould, T. J., Rao, A. N., Mazza, L. F., Morris, A. E., Núñez‐Álvarez, C., Hernández‐Ramírez, D., Bockenstedt, P. L., Liaw, P. C., Cabral, A. R., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39247 · Cited by 391
Yang, L.-Y., Luo, Q., Lu, L., Zhu, W.-W., Sun, H.-T., Wei, R., Lin, Z.-F., Wang, X.-Y., Wang, C.-Q., Lu, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0836-0 · Cited by 370
Gao, W., Xiong, Y., Li, Q., & Yang, H. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00508 · Cited by 353
Hydroxychloroquine in systemic lupus erythematosus (SLE)
Ponticelli, C., & Moroni, G. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1269168 · Cited by 345
Casasanta, M. A., Yoo, C. C., Udayasuryan, B., Sanders, B. E., Umaña, A., Zhang, Y., Peng, H., Duncan, A. J., Wang, Y., Li, L., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aba9157 · Cited by 327
Immune-mediated pathology in Duchenne muscular dystrophy
Rosenberg, A. S., Puig, M., Nagaraju, K., Hoffman, E. P., Villalta, S. A., Rao, V. A., Wakefield, L. M., & Woodcock, J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7322 · Cited by 304
Gottenberg, J.-E., Ravaud, P., Puéchal, X., Le Guern, V., Sibilia, J., Goeb, V., Larroche, C., Dubost, J.-J., Rist, S., Saraux, A., et al. (2014) · JAMA · doi:10.1001/jama.2014.7682 · Cited by 311
Toll-Like Receptor Pathways in Autoimmune Diseases
Chen, J.-Q., Szodoray, P., & Zeher, M. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8473-z · Cited by 315
TLR-Dependent Human Mucosal Epithelial Cell Responses to Microbial Pathogens
McClure, R., & Massari, P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00386 · Cited by 287
Cyclical palmitoylation regulates TLR9 signalling and systemic autoimmunity in mice
Ni, H., Wang, Y., Yao, K., Wang, L., Huang, J., Xiao, Y., Chen, H., Liu, B., Yang, C. Y., & Zhao, J. (2024) · Nature Communications · doi:10.1038/s41467-023-43650-z · Cited by 281
Tumor-derived exosomes modulate PD-L1 expression in monocytes
Haderk, F., Schulz, R., Iskar, M., Cid, L. L., Worst, T., Willmund, K. V., Schulz, A., Warnken, U., Seiler, J., Benner, A., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aah5509 · Cited by 298
Li, L., Acioglu, C., Heary, R. F., & Elkabes, S. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.10.007 · Cited by 283
Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents
Verbaanderd, C., Maes, H., Schaaf, M. B., Sukhatme, V. P., Pantziarka, P., Sukhatme, V., Agostinis, P., & Bouche, G. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.781 · Cited by 275
Recent clinical trends in Toll‐like receptor targeting therapeutics
Anwar, M. A., Shah, M., Kim, J., & Choi, S. (2019) · Medicinal Research Reviews · doi:10.1002/med.21553 · Cited by 275
Dai, X., Fan, Y., & Zhao, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02168-0 · Cited by 226
Herster, F., Bittner, Z., Archer, N. K., Dickhöfer, S., Eisel, D., Eigenbrod, T., Knorpp, T., Schneiderhan-Marra, N., Löffler, M. W., Kalbacher, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13756-4 · Cited by 267
Savva, A., & Roger, T. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00387 · Cited by 261
Toll-like Receptors in the Vascular System: Sensing the Dangers Within
Goulopoulou, S., McCarthy, C. G., & Webb, R. C. (2016) · Pharmacological Reviews · doi:10.1124/pr.114.010090 · Cited by 263
Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms
Ferreira, P. M. P., Sousa, R. W. R. D., Ferreira, J. R. D. O., Militão, G. C. G., & Bezerra, D. P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105582 · Cited by 227
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
Dima, A., Jurcut, C., Chasset, F., Felten, R., & Arnaud, L. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211073001 · Cited by 207
Izmirly, P., Kim, M., Friedman, D. M., Costedoat-Chalumeau, N., Clancy, R., Copel, J. A., Phoon, C. K. L., Cuneo, B. F., Cohen, R. E., Robins, K., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.045 · Cited by 226
Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies
Wenzel, J. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0272-0 · Cited by 218
New insights into mechanisms of therapeutic effects of antimalarial agents in SLE
Wallace, D. J., Gudsoorkar, V. S., Weisman, M. H., & Venuturupalli, S. R. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.106 · Cited by 220
Smith, C. K., Vivekanandan‐Giri, A., Tang, C., Knight, J. S., Mathew, A., Padilla, R. L., Gillespie, B. W., Carmona‐Rivera, C., Liu, X., Subramanian, V., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38703 · Cited by 216
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
Hydroxychloroquine in rheumatic autoimmune disorders and beyond
Nirk, E. L., Reggiori, F., & Mauthe, M. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012476 · Cited by 192
Toll-like receptors and chronic inflammation in rheumatic diseases: new developments
Joosten, L. A. B., Abdollahi-Roodsaz, S., Dinarello, C. A., O'Neill, L., & Netea, M. G. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.61 · Cited by 195
Smith, E. M. D., Lythgoe, H., Midgley, A., Beresford, M. W., & Hedrich, C. M. (2019) · Clinical Immunology · doi:10.1016/j.clim.2019.108274 · Cited by 194
Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis
Goh, F. G., & Midwood, K. S. (2012) · Rheumatology · doi:10.1093/rheumatology/ker257 · Cited by 192
Lupus neutrophils: ‘NET’ gain in understanding lupus pathogenesis
Knight, J. S., & Kaplan, M. J. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283546703 · Cited by 183
Willis, R., Seif, A., McGwin, G., Martinez-Martinez, L., González, E., Dang, N., Papalardo, E., Liu, J., Vilá, L., Reveille, J., et al. (2012) · Lupus · doi:10.1177/0961203312437270 · Cited by 186
Chamilos, G., Gregorio, J., Meller, S., Lande, R., Kontoyiannis, D. P., Modlin, R. L., & Gilliet, M. (2012) · Blood · doi:10.1182/blood-2012-01-401364 · Cited by 182
Toll-like receptors: potential targets for lupus treatment
Wu, Y.-W., Tang, W., & Zuo, J.-P. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.91 · Cited by 168
Type I interferon–mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy
Psarras, A., Emery, P., & Vital, E. M. (2017) · Rheumatology · doi:10.1093/rheumatology/kew431 · Cited by 168
Zhao, H., Zhou, J., Zhang, K., Chu, H., Liu, D., Poon, V. K.-M., Chan, C. C.-S., Leung, H.-C., Fai, N., Lin, Y.-P., et al. (2016) · Scientific Reports · doi:10.1038/srep22008 · Cited by 167
The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions
Shams, S., Martinez, J. M., Dawson, J. R. D., Flores, J. C., Gabriel, M., Garcia, G., de Guevara, A. L., Murray, K. M., Pacifici, N. J., Vargas, M. V., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.680043 · Cited by 175
Role of autophagy in immunity and autoimmunity, with a special focus on systemic lupus erythematosus
Pierdominici, M., Vomero, M., Barbati, C., Colasanti, T., Maselli, A., Vacirca, D., Giovannetti, A., Malorni, W., & Ortona, E. (2012) · The FASEB Journal · doi:10.1096/fj.11-194175 · Cited by 166
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Additionally, the antimalarial drug hydroxychloroquine (HCQ) may act as a TLR9 inhibitor [158].”
BackgroundMalaria and COVID-19: unmasking their ties
Hussein, M. I. H., Albashir, A. A. D., Elawad, O. A. M. A., & Homeida, A. (2020) · Malaria Journal · doi:10.1186/s12936-020-03541-w · Cited by 156
Ostendorf, T., Zillinger, T., Andryka, K., Schlee-Guimaraes, T. M., Schmitz, S. R., Marx, S., Bayrak, K., Linke, R., Salgert, S., Wegner, J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.009 · Cited by 158
Endobiont Viruses Sensed by the Human Host – Beyond Conventional Antiparasitic Therapy
Fichorova, R. N., Lee, Y. J., Yamamoto, H. S., Takagi, Y., Hayes, G. R., Goodman, R. P., Chepa-Lotrea, X., Buck, O. R., Murray, R. M., Kula, T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048418 · Cited by 154
Translating nucleic acid-sensing pathways into therapies
Junt, T., & Barchet, W. (2015) · Nature reviews. Immunology · doi:10.1038/nri3875 · Cited by 155
SARS-CoV-2–associated ssRNAs activate inflammation and immunity via TLR7/8
Salvi, V., Nguyen, H. O., Sozio, F., Schioppa, T., Gaudenzi, C., Laffranchi, M., Scapini, P., Passari, M., Barbazza, I., Tiberio, L., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150542 · Cited by 158
Novel Small Molecule Inhibitors of TLR7 and TLR9: Mechanism of Action and Efficacy In Vivo
Lamphier, M. S., Zheng, W., Latz, E., Spyvee, M. R., Hansen, H., Rose, J., Genest, M., Yang, H. Q., Shaffer, C. J., Zhao, Y., et al. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.089821 · Cited by 149
Antimalarial Drugs as Immune Modulators: New Mechanisms for Old Drugs
An, J., Minie, M., Sasaki, T., Woodward, J. J., & Elkon, K. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-043015-123453 · Cited by 150
Leroux, M., Desveaux, C., Parcevaux, M., Julliac, B., Gouyon, J., Dallay, D., Pellegrin, J., Boukerrou, M., Blanco, P., & Lazaro, E. (2015) · Lupus · doi:10.1177/0961203315591027 · Cited by 156
Small-molecule inhibition of TLR8 through stabilization of its resting state
Zhang, S., Hu, Z., Tanji, H., Jiang, S., Das, N., Li, J., Sakaniwa, K., Jin, J., Bian, Y., Ohto, U., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2518 · Cited by 154
Multifaceted effects of hydroxychloroquine in human disease
Olsen, N. J., Schleich, M. A., & Karp, D. R. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.01.001 · Cited by 153
Negative regulatory approaches to the attenuation of Toll-like receptor signaling
Anwar, M. A., Basith, S., & Choi, S. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.28 · Cited by 161
Rose, T., Grützkau, A., Hirseland, H., Huscher, D., Dähnrich, C., Dzionek, A., Ozimkowski, T., Schlumberger, W., Enghard, P., Radbruch, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201586 · Cited by 144
Hydroxychloroquine: An old drug with new relevance
Shippey, E. A., Wagler, V. D., & Collamer, A. N. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.17034 · Cited by 153
Webb, K., Peckham, H., Radziszewska, A., Menon, M., Oliveri, P., Simpson, F., Deakin, C. T., Lee, S. H., Ciurtin, C., Butler, G. E., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03167 · Cited by 155
An, J., Woodward, J. J., Lai, W., Minie, M., Sun, X., Tanaka, L., Snyder, J. M., Sasaki, T., & Elkon, K. B. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40559 · Cited by 142
Owen, A. M., Fults, J. B., Patil, N. K., Hernandez, A., & Bohannon, J. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.622614 · Cited by 149
Hashem, A. M., Alghamdi, B. S. A., Algaissi, A. A., Alshehri, F. S., Bukhari, A. I., Alfaleh, M. A., & Memish, Z. A. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101735 · Cited by 131
Park, S.-R., Kim, D., Han, S. H., Kang, M., Lee, J., Jeong, Y. L., Lee, S.-J., Kim, T., Ahn, S., Yoon, J., et al. (2014) · Infection and Immunity · doi:10.1128/iai.01226-13 · Cited by 127
Kuhn, A., Wenzel, J., & Weyd, H. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-013-8403-x · Cited by 139
Patinote, C., Karroum, N. B., Moarbess, G., Cirnat, N., Kassab, I., Bonnet, P., & Deleuze‐Masquéfa, C. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112238 · Cited by 138
mRNA therapeutics deliver a hopeful message
Zhong, Z., Cafferty, S. M., Combes, F., Huysmans, H., Temmerman, J. D., Gitsels, A., Vanrompay, D. C. G., Catani, J. P., & Sanders, N. N. (2018) · Nano Today · doi:10.1016/j.nantod.2018.10.005 · Cited by 133
Self-Assembled DNA Immunonanoflowers as Multivalent CpG Nanoagents
Zhang, L., Zhu, G., Mei, L., Wu, C. S., Qiu, L., Cui, C., Liu, Y., Teng, I., & Tan, W. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b06987 · Cited by 124
Yokogawa, N., Eto, H., Tanikawa, A., Ikeda, T., Yamamoto, K., Takahashi, T., Mizukami, H., Sato, T. Z., Yokota, N., & Furukawa, F. (2016) · Arthritis & Rheumatology · doi:10.1002/art.40018 · Cited by 122
Adipose Recruitment and Activation of Plasmacytoid Dendritic Cells Fuel Metaflammation
Ghosh, A. R., Bhattacharya, R., Bhattacharya, S., Nargis, T., Rahaman, O., Duttagupta, P., Raychaudhuri, D., Liu, C. S. C., Roy, S., Ghosh, P., et al. (2016) · Diabetes · doi:10.2337/db16-0331 · Cited by 120
Cell atlas of the foetal human heart and implications for autoimmune-mediated congenital heart block
Suryawanshi, H., Clancy, R. M., Morozov, P. S., Halushka, M. K., Buyon, J. P., & Tuschl, T. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz257 · Cited by 117
Tripathy, S., Dassarma, B., Roy, S., Chabalala, H. P., & Matsabisa, M. G. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106028 · Cited by 127
Kravvariti, E., Koutsogianni, A., Samoli, E., Sfikakis, P. P., & Tektonidou, M. G. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102491 · Cited by 115
Cutting Edge: Critical Role of Glycolysis in Human Plasmacytoid Dendritic Cell Antiviral Responses
Bajwa, G., DeBerardinis, R. J., Shao, B., Hall, B. E., Farrar, J. D., & Gill, M. A. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501557 · Cited by 116
Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger.
Devoldere, J., Dewitte, H., De Smedt, S. C., & Remaut, K. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.009 · Cited by 112
Systemic Lupus Erythematosus: A Review of the Disease and Treatment Options
Gurevitz, S. L., Snyder, J. A., Wessel, E. K., Frey, J., & Williamson, B. A. (2013) · The Consultant Pharmacist · doi:10.4140/tcp.n.2013.110 · Cited by 122
Nucleic acid‐sensing TLR s and autoimmunity: novel insights from structural and cell biology
Pelka, K., Shibata, T., Miyake, K., & Latz, E. (2016) · Immunological Reviews · doi:10.1111/imr.12375 · Cited by 110
Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase
Müller‐Calleja, N., Manukyan, D., Canisius, A., Strand, D. J., & Lackner, K. J. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210012 · Cited by 116
Altered RIG ‐I/ DDX58 ‐mediated innate immunity in dermatomyositis
Suárez‐Calvet, X., Gallardo, E., Nogales‐Gadea, G., Querol, L., Navas‐Madroñal, M., Díaz‐Manera, J., Rojas‐García, R., & Illa, I. (2014) · The Journal of Pathology · doi:10.1002/path.4346 · Cited by 108
Bocanegra, A., Ruiz‐de‐Angulo, A., Zabaleta, A., Blanco, N. G., Macarena, B., García-Granda, M. J., Padró, D., Llop, J., Arnáiz, B., Gato, M., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.003 · Cited by 110
The role of toll‐like receptor 4 (TLR4) in cancer progression: A possible therapeutic target?
Kashani, B., Zandi, Z., Pourbagheri‐Sigaroodi, A., Bashash, D., & Ghaffari, S. H. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30166 · Cited by 108
Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies
Robinson, G., Pineda‐Torra, I., Ciurtin, C., & Jury, E. C. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148552 · Cited by 115
Hedrich, C. M., Smith, E. M. D., & Beresford, M. W. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2018.02.001 · Cited by 119
Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine
Gies, V., Bekaddour, N., Dieudonné, Y., Guffroy, A., Frenger, Q., Gros, F., Rodero, M. P., Herbeuval, J., & Korganow, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01409 · Cited by 111
Systemic Lupus Erythematosus – A Disease with A Dysregulated Type I Interferon System
Hagberg, N., & Rönnblom, L. (2015) · Scandinavian Journal of Immunology · doi:10.1111/sji.12330 · Cited by 104
UNC93B1 variants underlie TLR7-dependent autoimmunity
Wolf, C., Lim, E. L., Mokhtari, M., Kind, B., Odainic, A., Lara-Villacanas, E., Koss, S., Mages, S., Menzel, K., Engel, K., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi9769 · Cited by 106
Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease
Golonka, R. M., Saha, P., Yeoh, B. S., Chattopadhyay, S., Gewirtz, A. T., Joe, B., & Vijay–Kumar, M. (2020) · Physiological Genomics · doi:10.1152/physiolgenomics.00033.2020 · Cited by 104
Nanocarrier vaccines for SARS-CoV-2
Machhi, J., Shahjin, F., Das, S., Patel, M., Abdelmoaty, M. M., Cohen, J. D., Singh, P. A., Baldi, A., Bajwa, N., Kumar, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.002 · Cited by 104
Staphylococcus aureus secretes immunomodulatory RNA and DNA via membrane vesicles
Rodriguez, B. V., & Kuehn, M. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-75108-3 · Cited by 99
Monteith, A. J., Kang, S., Scott, E., Hillman, K., Rajfur, Z., Jacobson, K., Costello, M. J., & Vilen, B. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513943113 · Cited by 99
Interferon‐alpha, immune activation and immune dysfunction in treated HIV infection
Cha, L., Berry, C., Nolan, D. A., Castley, A., Fernández, S., & French, M. A. (2014) · Clinical & Translational Immunology · doi:10.1038/cti.2014.1 · Cited by 97
Balak, D., van Doorn, M. B. A., Arbeit, R. D., Rijneveld, R., Klaassen, E. S., Sullivan, T., Brevard, J. A., Thio, H. B., Prens, E. P., Burggraaf, J., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.09.015 · Cited by 100
The contribution of macrophages to systemic lupus erythematosus
Ma, C., Xia, Y., Yang, Q., & Zhao, Y. (2019) · Clinical Immunology · doi:10.1016/j.clim.2019.06.009 · Cited by 100
The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases
Martinez, G. P., Zabaleta, M. E., Giulio, C. D., Charris, J., & Mijares, M. R. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200707132920 · Cited by 101
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects
Tang, C., Godfrey, T., Stawell, R. J., & Nikpour, M. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02886.x · Cited by 101
Metadata
- Authors
- Kužnik, A., Benčina, M., Švajger, U., Jeras, M., Rozman, B., & Jerala, R.
- Affiliations
- National Institute of Chemistry (SI)
- Blood Transfusion Centre of Slovenia (SI)
- Ljubljana University Medical Centre (SI)
- University of Ljubljana (SI)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04
- Volume
- 186
- Issue
- 8
- Pages
- 4794-4804
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2118400571
- Cited by
- 606
- References
- 40
- Citations by year
- 2026: 21 · 2025: 24 · 2024: 43 · 2023: 30 · 2022: 42 · 2021: 69 · 2020: 89 · 2019: 38 · 2018: 39 · 2017: 38 · 2016: 41 · 2015: 43 · 2014: 32 · 2013: 22 · 2012: 28
- FWCI
- 12.77
- Type
- journal article
- Language
- en
- Open access
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Repository of the University of Ljubljana (University of Ljubljana) (publishedVersion, other-oa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- antimalarial drugs, imidazoquinolines, chloroquine, hydroxychloroquine, quinacrine, TLR8, R848, nucleic acid binding, endosomal acidification, TLR9, TLR3, TLR7/8 agonist, systemic lupus erythematosus, autoimmune disease therapy, propidium iodide, bafilomycin
- MeSH terms
- Animals, Antimalarials, Binding, Competitive, Cell Line, Cells, Cultured, Chloroquine, Culture Media, Humans, Hydrogen-Ion Concentration, Imidazoles, Nucleic Acids, Quinacrine, Quinolines, Endosomes, Transfection, Cytokines, Serum, Toll-Like Receptors, Toll-Like Receptor 3, Toll-Like Receptor 7, Toll-Like Receptor 8, Toll-Like Receptor 9, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.